Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Published:2024-07-26 Issue: Volume: Page:1-9
ISSN:0163-5581
Container-title:Nutrition and Cancer
language:en
Short-container-title:Nutrition and Cancer

Author:

Turcott Jenny G.¹,Miyagui Sayako M.¹,Gutiérrez Torres Salvador²,Cárdenas-Fernández Daniela¹,Caballé-Perez Enrique¹,Rios-Garcia Eduardo¹,Cardona Andrés F.³,Rolfo Christian⁴,Arrieta Oscar¹⁵

Affiliation:

1. Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

2. Radio-oncology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

3. Thoracic Oncology Unit and Direction of Research, Science, and Education, Luis Carlos Sarmiento, Bogotá, Colombia

4. Thoracic Oncology Center, Tisch Cancer Center, Mount Sinai Hospital System & Icahn School of Medicine, New York, New York, USA

5. Personalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/01635581.2024.2382390

Reference29 articles.

1. Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)

2. Lung Cancer in Mexico

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

5. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer